- Professor, Medicine - (Clinical Scholar Track)
Dr Lassar is Professor of Medicine, University of Arizona College of Medicine and Staff Clinical and Interventional Cardiologist at Banner University Medical Center South Campus. He completed his undergraduate BA at Washington University in St. Louis cum laude, attended St. Louis University School of Medicine where he was President of AOA and was graduated with MD magna cum laude in 1977, then returned to Washington University Barnes-Jewish Hospital for residency in Internal Medicine, in which he is board certified, and subsequently completed training and board certification in Cardiovascular Diseases at University of Chicago Hospitals and Clinics. In 1982 Dr Lassar began a career in clinical care and clinical research, and was a founder of the field of Interventional Cardiology, now a subspecialty of CV disease then in its infancy. As Asst. Professor of Medicine at University of Wisconsin Milwaukee Clinical Campus Aurora St. Luke’s-Sinai-Samaritan Hospitals, he was Co-Director of Cardiac Catheterization and Intervention developing research interests and publishing in the areas of coronary flow and physiology, management of acute and chronic ischemic heart disease, advanced coronary imaging, and new device development. In 1988 he was recruited to serve as Director of Cardiac Catheterization and Intervention at Mt. Sinai Medical Center of Cleveland, and subsequently served as Associate Professor of Medicine, Associate Director Adult Cardiac Catheterization and Intervention from 1997 until 2013 at University Hospitals of Cleveland, Case Western Reserve Medical School of Medicine before joining the medical staff at University of Arizona in 2014. Dr Lassar has continued to focus his clinical and academic interests in the development of new coronary devices and platforms, vascular closure devices, platelet pharmacology, application of platelet function testing to clinical management of coronary artery disease, and clinical trials of new generation antiplatelet drugs. Dr Lassar is an active member of the American College of Cardiology (ACC), and was until recently an elected member of the Ohio ACC Board of Governors. He is a Fellow of the American Heart Association (AHA), and Society for Cardiac Angiography and Interventions (SCAI) over the years having served on multiple leadership and steering committees. He is subspecialty board certified in Interventional Cardiology.
- M.D. Medicine
- St. Louis University School of Medicine, St. Louis, Missouri, United States
- B.A. English Literature
- Washington University, St. Louis, Missouri, United States
- University of Arizona Health Network - South Campus (2015 - Ongoing)
- University of Arizona Health Network - South Campus (2014 - Ongoing)
- Banner University Medical Center South Campus (2014 - Ongoing)
- UHHS Ahuja Medical Center (2011 - 2013)
- UHHS St. John's Westshore Hospital (2005)
- Case Western Reserve Medical School (2002 - 2013)
- St. Vincent's Charity Hospital (2001 - 2004)
- UHHS Geauga Hospital (1998 - 1999)
- University Hospitals of Cleveland (1997 - 2013)
- Adler Holland, Inc/Case Western Reserve Medical School (1988 - 2002)
- Mt. Sinai Medical Center of Cleveland (1988 - 1997)
- University of Wiscoonsin Medical School-Milwaukee Campus (1983 - 1988)
- University of Illinois Medical Center (1983 - 1984)
- Aurora Sinai Samaritan Medical Center, University of Wisconsin, Milwaukee Medical Campus (1982 - 1988)
- University of Wiscoonsin Medical School- Mt. Sinai Medical Center (1982 - 1983)
- University of Chicago - Pritzker School of Medicine (1980 - 1982)
- Washington University School of Medicine (1977 - 1980)
- Teaching Academic Award
- Mt. Sinai Medical Center, Fall 1995
- Society for Cardiac Angiography and Interventions (11/18/1988 - present). (Member: Education-Online Core Curriculum Committe, Interventional Training Standards Committe, Public Relations-SecondsCount.org)., Fall 1988
- Associate Member
- American Federation for Clinical Research(01/01/1982 - 08/01/1988) inactive, Winter 1982
- Alpha Sigma Nu Academic Honor Society
- Fall 1977
- Alpha Omega Alpha
- Illinois State Scholarship Foundation Honorary, Fall 1976
- President - Alpha Omega Alpha
- St. Louis University Chapter, Fall 1976
- America's Top Cardiologists
- Winter 2017
- AmTop Cardiologists
- Winter 2014
- Americas Top Cardiologists
- 2013-2016, Fall 2013
- Cleveland's "Top Docs" Award
- Fall 2013
- Member Elect
- Ohio ACC Board of Trustees-Leadership Council 2013-2015., Fall 2013
Licensure & Certification
- Sub-specialty Certification, Interventional Cardiology (2001)
- Ten Year Recertification, Interventional Cardiology (2011)
- Certification, National Board of Medical Examiners (1978)
- Certification, American Board of Internal Medicine (1980)
- Medical License, Illinois State Board of Healing Arts (1980)
- Medical License, Wisconsin State Board of Healing Arts (1982)
- Medical License, Missouri State Board of Healing Arts (1977)
- Certification, American Board of Internal Medicine (2014)
- License, Arizona Medical Board (2013)
- Certification, American Board of Internal Medicine - Subspecialty Cardiovascular Diseases (1982)
- License, Ohio State Board of Health Arts (1988)
- Certification, National Board of Physicians and Surgeons; Cardiology, IC (2016)
Dr Lassar has continued to focus his clinical and academic interests in the development of new coronary devices and platforms, vascular closure devices, platelet pharmacology, application of platelet function testing to clinical management of coronary artery disease, and clinical trials of new generation antiplatelet drugs.
No activities entered.
- Lee, J. Z., Singh, N., Ortega, G., Low, S. W., Kanakadandi, U., Fortuin, F. D., Lassar, T., & Lee, K. S. (2015). Composite outcomes in 2.25-mm drug eluting stents: a systematic review. Cardiovascular revascularization medicine : including molecular interventions, 16(4), 237-42.More infoCoronary atherosclerosis often involves small-caliber coronaries, yet the safety and efficacy of 2.25-mm DES have been poorly defined, with a general lack of separation of 2.25 with 2.5-mm performance. No randomized head-to-head 2.25 mm DES studies have been reported. There are several single-arm prospective studies, and we aim to systematically review all published specific 2.25-mm data to estimate composite DES-specific performance and highlight current knowledge gaps.
- Farkouh, M. E., Farkouh, M. E., Domanski, M., Domanski, M., Sleeper, L. A., Sleeper, L. A., Siami, F. S., Siami, F. S., Dangas, G., Dangas, G., Mack, M., Mack, M., Yang, M., Yang, M., Cohen, D. J., Cohen, D. J., Rosenberg, Y., Rosenberg, Y., Solomon, S. D., , Solomon, S. D., et al. (2012). Strategies for multivessel revascularization in patients with diabetes. The New England journal of medicine, 367(25), 2375-84.More infoIn some randomized trials comparing revascularization strategies for patients with diabetes, coronary-artery bypass grafting (CABG) has had a better outcome than percutaneous coronary intervention (PCI). We sought to discover whether aggressive medical therapy and the use of drug-eluting stents could alter the revascularization approach for patients with diabetes and multivessel coronary artery disease.
- Adler, D. S., Lazarus, H., Nair, R., Goldberg, J. L., Greco, N. J., Lassar, T., Laughlin, M. J., Das, H., & Pompili, V. J. (2011). Safety and efficacy of bone marrow-derived autologous CD133+ stem cell therapy. Frontiers in bioscience (Elite edition), 3, 506-14.More infoThe Phase I clinical study was designed to assess the safety and feasibility of a dose escalating intracoronary infusion of autologous bone marrow (BM)-derived CD133+ stem cell therapy to the patients with chronic total occlusion (CTO) and ischemia. Nine patients were received CD133+ cells into epicardial vessels supplying collateral flow to areas of viable ischemic myocardium in the distribution of the CTO. There were no major adverse cardiac events (MACE), revascularization, re-admission to the hospital secondary to angina, or acute myocardial infarction (AMI) for the 24-month period following cellular infusion. In addition, there were no periprocedural infusion-related complications including malignant arrhythmias, loss of normal coronary blood flow or acute neurologic events. Cardiac enzymes were negative in all patients. There was an improvement in the degree of ischemic myocardium, which was accompanied by a trend towards reduction in anginal symptoms. Intracoronary infusion of autologous CD133+ marrow-derived cells is safe and feasible. Cellular therapy with CD133+ cells to reduce anginal symptoms and to improve ischemia in patients with CTO awaits clinical investigation in Phase II/III trials.
- Lassar, T. A., Simon, D. I., & Croce, K. (2011). Optimizing antiplatelet therapy following percutaneous coronary intervention: clinical pathways for platelet function testing. Reviews in cardiovascular medicine, 12 Suppl 1, S23-33.More infoCurrent guidelines recommend dual antiplatelet therapy (DAPT), which includes aspirin and a platelet P2Y(12) adenosine diphosphate (ADP) receptor antagonist, for treatment of patients with acute coronary syndrome and following percutaneous coronary intervention (PCI). Although DAPT significantly reduces stent thrombosis and major adverse cardiovascular events (MACE), there is considerable interindividual variability in the degree of platelet inhibition achieved with the most widely used ADP receptor antagonist, clopidogrel, and high on-treatment platelet activity in the setting of clopidogrel therapy (hyporesponsiveness) is associated with increased adverse cardiovascular events following PCI. Personalized tailoring of antiplatelet therapy guided by patient management algorithms and/or platelet function testing has the potential to reduce MACE and stent thrombosis. This article outlines specific algorithms for using potent new antiplatelet agents, such as prasugrel and ticagrelor, and platelet function "test and treat-to-target" strategies to reduce adverse cardiovascular events following PCI.
- Wallentin, L., Wallentin, L., Becker, R. C., Becker, R. C., Budaj, A., Budaj, A., Cannon, C. P., Cannon, C. P., Emanuelsson, H., Emanuelsson, H., Held, C., Held, C., Horrow, J., Horrow, J., Husted, S., Husted, S., James, S., James, S., Katus, H., , Katus, H., et al. (2009). Ticagrelor versus clopidogrel in patients with acute coronary syndromes. The New England journal of medicine, 361(11), 1045-57.More infoTicagrelor is an oral, reversible, direct-acting inhibitor of the adenosine diphosphate receptor P2Y12 that has a more rapid onset and more pronounced platelet inhibition than clopidogrel.
- Christensen, C. W., Christensen, C. W., Rosen, L. B., Rosen, L. B., Gal, R. A., Gal, R. A., Haseeb, M., Haseeb, M., Lassar, T. A., Lassar, T. A., Port, S. C., & Port, S. C. (1991). Coronary vasodilator reserve. Comparison of the effects of papaverine and adenosine on coronary flow, ventricular function, and myocardial metabolism. Circulation, 83(1), 294-303.More infoTo evaluate coronary flow reserve during cardiac catheterization, intracoronary adenosine and papaverine have been used in the clinical setting. Although papaverine maximizes coronary blood flow, it induces several toxic side effects that reduce its desirability as a coronary dilator. This investigation was designed to compare the subselective intracoronary administration of papaverine with that of adenosine in an animal model. In dogs (n = 34), we studied the effects of each agent on hemodynamics, regional myocardial blood flow, contractility (sonomicrometric and echocardiographic), metabolism (coronary arterial and venous lactate and tissue high-energy phosphates), and electrocardiographic (ST and QT intervals) parameters. Barbiturate and morphine anesthesia/analgesia was induced, and a left thoracotomy was performed. An arterial shunt was created from the left carotid artery to the left anterior descending coronary artery. Two separate groups were studied: group 1 (n = 16) for regional myocardial blood flow and mechanical function and group 2 (n = 18) for biochemical measurements. Adenosine (67 +/- 2 micrograms/min) or papaverine (6 +/- 1 mg/min) was infused into the coronary shunt at a rate of 0.5 + 0.1 ml/min for a maximum duration of 3.5 minutes. Regional myocardial blood flows were determined at control (predrug) and maximal coronary flow using radiolabeled microspheres. All hemodynamic, wall motion, biochemical, and electrocardiographic parameters were also measured at these times. Both drugs produced comparable increases in total and regional coronary blood flows (adenosine, 1.21 +/- 0.15 to 4.83 +/- 0.36 ml/min/g; papaverine, 1.21 +/- 0.05 to 4.89 +/- 0.28 ml/min/g) upon infusion into the left anterior descending coronary artery. Papaverine produced significant (p less than 0.05) changes in subendocardial ST segment electrocardiogram (-2.5 mm), QT prolongation (8 +/- 2%), myocardial creatine phosphate (47% decrease), and coronary sinus serum lactate (277% increase) compared with control. In addition, intracoronary papaverine induced an abnormal contractile pattern. No significant changes in any of these parameters (i.e., ST segment, QT prolongation, myocardial creatine phosphate level, or lactate level) were observed with intracoronary adenosine infusions. We conclude that intracoronary adenosine is comparable to papaverine for maximizing coronary blood flow without the deleterious properties observed with intracoronary papaverine.
- Lassar, T. A., & Lassar, T. A. (1991). Avoidance of vascular complications during transfemoral catheterization. Catheterization and cardiovascular diagnosis, 22(2), 156.
- Christensen, C. W., Christensen, C. W., Lassar, T. A., Lassar, T. A., Daley, L. C., Daley, L. C., Rieder, M. A., Rieder, M. A., Schmidt, D. H., & Schmidt, D. H. (1990). Regional myocardial blood flow with a reperfusion catheter and an autoperfusion balloon catheter during total coronary occlusion. American heart journal, 119(2 Pt 1), 242-8.More infoWe investigated the ability of two new coronary perfusion catheters to maintain regional myocardial blood flow throughout a 90-minute period of occlusion. In 21 dogs (group I = total occlusion control; group II = reperfusion catheter; group III = autoperfusion balloon catheter) we studied regional blood flow, distal coronary perfusion pressure, infarct size, and red blood cell hemolysis after placement of either catheter into the left anterior descending coronary artery. Regional (microsphere) blood flow showed a reduction in transmural blood flow during occlusion in comparison to baseline values (1.07 +/- 0.12 to 0.81 +/- 0.11 and 1.01 +/- 0.16 to 0.73 +/- 0.08 ml/min subendocardial perfusion for groups II and III, respectively). Comparable changes in blood flow were observed in the subepicardial and midmyocardial regions. Distal coronary perfusion pressures were reduced by 26% and 28% for groups II and III, respectively. Both catheters prevented significant infarction and maintained adequate regional myocardial blood flow throughout the 90-minute period of occlusion without significant complications of clotting or destruction of erythrocytes.
- Kent, K. M., Kent, K. M., Cleman, M. W., Cleman, M. W., Cowley, M. J., Cowley, M. J., Forman, M. B., Forman, M. B., Jaffe, C. C., Jaffe, C. C., Kaplan, M., Kaplan, M., King, S. B., King, S. B., Krucoff, M. W., Krucoff, M. W., Lassar, T., Lassar, T., McAuley, B., & McAuley, B. (1990). Reduction of myocardial ischemia during percutaneous transluminal coronary angioplasty with oxygenated Fluosol. The American journal of cardiology, 66(3), 279-84.More infoThe effects of perfusion of an oxygen-carrying perfluorochemical emulsion (Fluosol) in alleviating symptoms of myocardial ischemia during balloon occlusion were examined in a multicenter trial of 245 patients. Severe anginal pain occurred less frequently in patients receiving Fluosol perfusion (21%) than in those receiving routine angioplasty (34%) (p less than 0.05). ST-segment changes at balloon deflation in routine angioplasty patients were significantly greater than in patients who received oxygenated Fluosol perfusion (2.2 +/- 1.2 vs 1.7 +/- 0.9 mm; p less than 0.03). Profound regional wall dysfunction (-561 +/- 224 U) was observed in routine angioplasty patients by 2-dimensional echocardiography. Patients receiving oxygenated Fluosol perfusion, however, maintained near baseline levels of ventricular function (-61 +/- 335 U) during occlusion (p less than 0.0001). Mean global left ventricular ejection fraction was preserved at baseline levels during balloon inflation in patients perfused with oxygenated Fluosol but decreased significantly (p less than 0.001) during occlusion in routine angioplasty patients. A total of 26 complications (19 routine group; 7 perfusion group) was reported. Adverse responses to the perfusate were infrequent, occurring in 1.6 and 2.0% of patients after the test dose and during perfusion, respectively. Thus, transcatheter perfusion with an oxygen-carrying perfluorochemical emulsion is effective in alleviating myocardial ischemia during angioplasty and can be safely administered in this patient population.
- Christensen, C. W., Christensen, C. W., Reeves, W. C., Reeves, W. C., Lassar, T. A., Lassar, T. A., Schmidt, D. H., & Schmidt, D. H. (1988). Inadequate subendocardial oxygen delivery during perfluorocarbon perfusion in a canine model of ischemia. American heart journal, 115(1 Pt 1), 30-7.More infoPerfusion of the coronary artery distal to an occlusion was performed in 16 canine preparations to compare the mechanical perfusion of autologous blood to the perfluorocarbon fluosol DA, 20% emulsion (FDA-20). Both substances were perfused under similar conditions (30, 60, and 80 ml/min) and regional electrograms, contractility, and coronary perfusion were measured relative to native coronary perfusion. Autologous blood (60 and 80 ml/min) produced a significant increase in regional (epicardial, midmyocardial, and endocardial) and transmural flow, but not in the endocardial/epicardial perfusion ratio. No other significant changes were observed during autologous blood perfusion. In contrast, FDA-20 perfusion resulted in significant ST depression (-1.8 +/- 0.2, -1.7 +/- 0.2, and -1.3 +/- 0.3 mm) at 30, 60, and 80 ml/min, respectively. FDA-20 also induced a significant decrease in distal diastolic coronary pressure and resistance, a significant decrease in the endocardial/epicardial perfusion ratio at all three perfusion rates, and a significant reduction in delivery of O2 to the subendocardium. These results indicate that autologous blood perfusion of the distal coronary artery during occlusion preserves myocardial function to a better degree than does FDA-20.
- Lotun, K., Lassar, T., Lee, K. S., Kannan, A., Poongkunran, M., & Sundararajan, S. (2016, March). Comparison Of Drug Coated Balloons And Drug Eluting Stents In In-stent Restenosis- A Meta Analysis.. American College of Cardiology Scientific Sessions.